WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year
WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year
SHANGHAI, July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has again been named as a constituent company of the FTSE4Good Index Series. This marks the fourth consecutive year the company has been included in the Index for its outstanding sustainability performance.
2024年7月10日上海 / PRNewswire——全球領先的合同研究、開發及製造組織（CRDMO）藥明生物（"WuXi Bio"）（2269.HK）宣佈，已連續第四年入選FTSE4Good指數系列的成分公司。這標誌着該公司因其傑出的可持續性表現再次兼入該指數。
Launched in 2001 by the global index and data provider FTSE Russell, which is wholly owned by the London Stock Exchange Group, the FTSE4Good Index Series is designed to measure the performance of companies demonstrating good sustainability practices. Inclusion in the FTSE4Good Index Series is based on independent analysis of data from over 8,000 securities in 47 developed and emerging countries. Over the past years, WuXi Biologics has realized substantial improvements in its overall FTSE Russell ESG score, as well as its theme scores. The company's ESG score in 2024 achieved the top 7% in its industry.
FTSE4Good指數系列由全球指數和數據提供商FTSE Russell於2001年推出，其全資擁有者是倫敦證券交易所集團。該指數系列旨在衡量展示良好可持續性實踐的公司的表現。FTSE4Good指數系列的入選基於對47個發達和新興國家的超過8,000種證券的數據進行的獨立分析。過去的幾年中，藥明生物在其整體FTSE Russell ESG評分及其主題評分上實現了實質性的提高。該公司2024年的ESG評分在其行業中達到了前7％。
Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, "We are very proud to be acknowledged again by FTSE Russell as a constituent of the FTSE4Good Index Series. It underscores our firm commitment to sustainability, demonstrating the success of our comprehensive ESG strategy and our effective implementation of ESG approaches. Moving forward, we will continue to regard sustainability as the cornerstone of business growth, delivering consistently strong performance for the common good of the global community."
藥明生物首席執行官兼ESG委員會主席陳際琪博士表示：“我們感到非常自豪能夠再次被FTSE Russell確認爲FTSE4Good指數系列的成分公司。這凸顯了我們對可持續性的堅定承諾，充分證明我們的全面ESG策略的成功實施以及我們ESG方法的有效應用。未來，我們將繼續將可持續性視爲業務增長的基石，爲全球社區的共同利益提供始終如一的強勁表現。”
In line with the United Nations Sustainable Development Goals, WuXi Biologics has been making steady progress in pursuing sustainable development, which has been recognized by major ESG rating agencies. In the past year, the company was added to the S&P Dow Jones Sustainability World Index and Emerging Markets Index; granted a "AAA" rating from MSCI ESG Ratings; awarded the distinguished Platinum Medal by EcoVadis; recognized as an Industry and Regional Top-Rated Company by Sustainalytics; named to the CDP Water Security "A list"; and awarded an "A-" CDP Climate Change score.
藥明生物按照聯合國可持續發展目標，不斷推進可持續發展，得到了主要ESG評級機構的認可。在過去的一年中，該公司被加入了標普道瓊斯可持續發展世界指數和新興市場指數；被MSCI ESG評級授予了“AAA”評級；榮獲了EcoVadis頒發的傑出鉑金獎章；榮獲了Sustainalytics評選的行業和區域最佳評級公司；入選CDP水安全“A清單”；並獲得了“A-”CDP氣候變化評分。
About WuXi Biologics
關於藥明生物
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
藥明生物（2269.HK）是一家領先的全球合同研究、開發及製造組織（CRDMO），提供端到端的解決方案，使合作伙伴能夠從概念到商業化研製和製造生物製品，造福世界各地的患者。
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2023, WuXi Biologics is supporting 698 integrated client projects, including 24 in commercial manufacturing.
藥明生物在中國、美國、愛爾蘭、德國和新加坡擁有超過12,000名技術熟練的員工，利用其技術和專業知識，爲客戶提供高效、經濟的生物製品研發和製造解決方案。截至2023年12月31日，藥明生物正在支持698個結合式客戶項目，其中24個爲商業製造項目。
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to be an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
藥明生物將環境、社會和治理（ESG）責任視爲我們的核心價值觀和業務戰略的不可分割的組成部分，並且我們旨在成爲生物製品CRDMO行業的ESG領袖。我們的設施採用下一代生物製造技術和清潔能源。我們還建立了由首席執行官領導的ESG委員會，以引導全面ESG策略及其實施，增強我們對可持續性的承諾。
For more information about WuXi Biologics, please visit: .
欲了解更多有關藥明生物的信息，請訪問：。
SOURCE WuXi Biologics
來源：藥明生物